Trial watch: phase II and phase III attrition rates 2011-2012.
John Arrowsmith,Philip Miller +1 more
Reads0
Chats0
About:
This article is published in Nature Reviews Drug Discovery.The article was published on 2013-08-01 and is currently open access. It has received 549 citations till now. The article focuses on the topics: MEDLINE.read more
Citations
More filters
Journal ArticleDOI
The ChEMBL database in 2017.
Anna Gaulton,Anne Hersey,Michal Nowotka,A. Patrícia Bento,Jon Chambers,David Mendez,Prudence Mutowo,Francis Atkinson,Louisa J. Bellis,Elena Cibrian-Uhalte,Mark Davies,Nathan Dedman,Anneli Karlsson,María Paula Magariños,John P. Overington,George Papadatos,Ines Smit,Andrew R. Leach +17 more
TL;DR: ChEMBL is an open large-scale bioactivity database that includes the annotation of assays and targets using ontologies, the inclusion of targets and indications for clinical candidates, addition of metabolic pathways for drugs and calculation of structural alerts.
Journal ArticleDOI
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao,Joshua M. Korn,Stephane Ferretti,John Monahan,Youzhen Wang,Mallika Singh,Mallika Singh,Chao Zhang,Chao Zhang,Christian Schnell,Guizhi Yang,Yun Zhang,O. Alejandro Balbin,Stephanie Barbe,Hongbo Cai,Fergal Casey,Susmita Chatterjee,Derek Y. Chiang,Shannon Chuai,Shawn Cogan,Scott D. Collins,Ernesta Dammassa,Nicolas Ebel,Millicent Embry,John Green,Audrey Kauffmann,Colleen Kowal,Rebecca Leary,Joseph Lehar,Ying Liang,Alice Loo,Edward Lorenzana,E. Robert McDonald,Margaret E. McLaughlin,Jason Merkin,Ronald Meyer,Tara L. Naylor,Montesa Patawaran,Anupama Reddy,Anupama Reddy,Claudia Roelli,David A. Ruddy,Fernando Salangsang,Francesca Santacroce,Angad P Singh,Yan Tang,Walter Tinetto,Sonja Tobler,Roberto Velazquez,Kavitha Venkatesan,Fabian Von Arx,Hui Qin Wang,Zongyao Wang,Marion Wiesmann,Daniel Wyss,Fiona Xu,Hans Bitter,Peter Atadja,Emma Lees,Francesco Hofmann,En Li,Nicholas Keen,Robert Cozens,Michael Rugaard Jensen,Nancy Pryer,Nancy Pryer,Juliet Williams,William R. Sellers +67 more
TL;DR: The results suggest that PCTs may represent a more accurate approach than cell line models for assessing the clinical potential of some therapeutic modalities and could potentially improve preclinical evaluation of treatmentmodalities and enhance the ability to predict clinical trial responses.
Journal ArticleDOI
The support of human genetic evidence for approved drug indications
Matthew R. Nelson,Hannah Tipney,Jeffery L. Painter,Judong Shen,Paola Nicoletti,Yufeng Shen,Aris Floratos,Pak C. Sham,Mulin Jun Li,Junwen Wang,Lon R. Cardon,John C. Whittaker,Philippe Sanseau +12 more
TL;DR: It is estimated that selecting genetically supported targets could double the success rate in clinical development, and using the growing wealth of human genetic data to select the best targets and indications should have a measurable impact on the successful development of new drugs.
Journal ArticleDOI
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook,Dearg S. Brown,Robert Alexander,Ruth March,Paul Morgan,Gemma Satterthwaite,Menelas N. Pangalos +6 more
TL;DR: A comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010 allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which are described as the five 'R's'.
Journal ArticleDOI
Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning.
TL;DR: Common approaches to 3D culture are reviewed, the significance of 3D cultures in drug resistance and drug repositioning is discussed and some of the challenges of applying 3D cell cultures to high-throughput drug discovery are addressed.